Consolidated Condensed Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2025	Jun. 29, 2024	Jun. 28, 2025	Jun. 29, 2024
Income Statement [Abstract]
Net sales	$ 147,660	$ 151,217	$ 271,536	$ 280,674
Cost of sales (including depreciation and amortization of $10,603, $11,021, $20,868 and $21,046, respectively)	45,570	47,578	86,390	88,655
Gross profit	102,090	103,639	185,146	192,019
Selling, general and administrative expense	79,110	96,668	152,612	175,443
Research and development expense	3,172	4,210	6,183	6,837
Change in fair value of contingent consideration	0	300	0	595
Depreciation and amortization	1,439	2,064	3,032	3,819
Impairment of assets	0	31,870	0	31,870
Loss on disposals	1	0	82	0
Operating income (loss)	18,368	(31,473)	23,237	(26,545)
Interest expense, net	7,494	9,924	15,003	20,263
Other expense, net	561	159	1,338	222
Other expense	8,055	10,083	16,341	20,485
Income (loss) before income taxes	10,313	(41,556)	6,896	(47,030)
Income tax expense (benefit), net	1,041	(7,339)	946	(6,432)
Net income (loss)	9,272	(34,217)	5,950	(40,598)
(Income) loss attributable to noncontrolling interest	(1,813)	8,535	(1,128)	10,026
Net income (loss) attributable to Bioventus Inc.	7,459	(25,682)	4,822	(30,572)
Change in foreign currency translation adjustments	1,593	(426)	2,226	(1,011)
Comprehensive income (loss)	10,865	(34,643)	8,176	(41,609)
Comprehensive income (loss) attributable to noncontrolling interest	(2,118)	8,619	(1,555)	10,226
Comprehensive income (loss) attributable to Bioventus Inc.	$ 8,747	$ (26,024)	$ 6,621	$ (31,383)
Loss per share of Class A common stock
Loss per share of class A common stock, basic (in dollars per share)	$ 0.11	$ (0.40)	$ 0.07	$ (0.48)
Loss per share of class A common stock, diluted (in dollars per share)	$ 0.11	$ (0.40)	$ 0.07	$ (0.48)
Weighted-average shares of Class A common stock outstanding
Basic (in shares)	66,500,433	64,056,759	66,258,679	63,720,342
Diluted (in shares)	68,536,759	64,056,759	68,765,591	63,720,342